FOLH1 and metastatic neoplasm: Our panel discussed the fact that recent trials in the setting of nmCRPC used conventional imaging for staging and that with the wider used of PET-PSMA we are seeing fewer patients with rising PSA and no radiologic evidence of metastatic disease.